Drug Profile


Alternative Names: DCR-M1711; DCR-MYC

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dicerna Pharmaceuticals
  • Class Antineoplastics; Small interfering RNA
  • Mechanism of Action Proto oncogene protein c-myc inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatocellular carcinoma; Multiple myeloma; Non-Hodgkin's lymphoma; Pancreatic cancer; Solid tumours

Most Recent Events

  • 03 Aug 2017 Dicerna Pharmaceuticals terminates a phase I trial in Non-Hodgkin's lymphoma, Solid tumours and Multiple myeloma (Second-line therapy or greater) due to sponsor decision in USA (IV) (NCT02110563)
  • 03 Aug 2017 Dicerna Pharmaceuticals terminates a phase-I/II clinical trial due to sponsor decision in Hepatocellular carcinoma (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA, Singapore and South Korea (IV) (NCT02314052)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top